SOUL Findings Highlight Cardiovascular Benefits Beyond Glycemic Control With Oral GLP-1
March 30th 2025Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.